What is King Pharmaceuticals's income from discontinued ops?

King Pharmaceuticals (KG) reported income from discontinued ops of -$0.06 in Q1 2026.

What does income from discontinued ops mean?

Gains or losses from business segments that have been sold, abandoned, or classified as held for sale, reported net of applicable income taxes.

Tiptree Inc.TIPT

——

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Operating cash flow-$15.1M-1,628%

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Net margin131.5%—

Return on equity90.8%—

Debt / equity1.5×—

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is King Pharmaceuticals's income from discontinued ops?: King Pharmaceuticals (KG) reported income from discontinued ops of -$0.06 in Q1 2026.
What does income from discontinued ops mean?: Gains or losses from business segments that have been sold, abandoned, or classified as held for sale, reported net of applicable income taxes.